Inhibition of the first peak of p38MAPK activity blocked blister formation, whereas inhibition of the second peak failed to block blistering in vivo. Neonatal mice (n = 3 per treatment group) were injected intradermally with 1) PF IgG only, 2) the p38MAPK inhibitor SB202190 2 h before PF IgG injection, or 3) the p38MAPK inhibitor SB202190 4 h after PF IgG injection. After 18 h, the skin of the three different groups was examined. A, skin biopsies examined by routine hematoxylin and eosin (H&E, ×20) and by direct immunofluorescence (IF) using phospho-p38MAPK (P-P38MAPK) antibodies. Blistering is observed in PF IgG-treated mice but not in inhibitor-pretreated mice. In contrast, blistering is observed when the inhibitor is administered 4 h after PF IgG. The arrow shows increased phospho-p38MAPK IF signal in PF IgG-treated mice. B, extracts from skin biopsies of three mice (lanes 1-3) from each treatment group were probed by immunoblot with antibodies to phospho-p38MAPK and total p38MAPK. C, signal intensity from the ECL reaction for each band was quantified with a GeneGnome HR scanner (Syngene) using GeneSnap software (n = 3, S.D. shown by error bars). The phospho-p38MAPK signal was normalized to total p38MAPK for each sample. p values (*, p < 0.001; **, p < 0.001) were calculated using the Student's t test. D, neonatal mice were treated with 1) control (Con) IgG, 2) PF IgG, or 3) the p38MAPK inhibitor SB202190 4 h after PF IgG injection to block the second peak of p38MAPK activation. After 30 h, extracts from skin biopsies were probed with antibodies to phospho-p38MAPK, total p38MAPK, or cleaved caspase 3. In the mice treated with the inhibitor 4 h after PF IgG, the second peak of p38MAPK activity and the increase in caspase 3 cleavage are blocked.